CRISPR Therapeutics' GAAP loss for 3 months of 2022 was $179.217 million, up 58.4% from $113.163 million in the prior year. Revenue increased 74.4% to $940 million from $539 million a year earlier.
CRISPR Therapeutics' GAAP loss for 3 months of 2022 was $179.217 million, up 58.4% from $113.163 million in the prior year. Revenue increased 74.4% to $940 million from $539 million a year earlier. 
ir.crisprtx.com
English (US) 